Considering the risks of substances that are carcinogenic, mutagenic, or toxic to reproduction, the Commission shall appoint the Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products to formulate an opinion on the use of these categories of substance as auxiliary agents in medicinal products for human use; the legal basis for this is Article 5(3) and Article 57(1)(p) of Regulation (EC) No 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
The Commission shall forward the opinion of the Committee for Medicinal Products for Human Use to the European Parliament and to the Council.
Within six months of the delivery of the opinion by the Committee for Medicinal Products for Human Use, the Commission shall inform the European Parliament and the Council about the measures that it plans to put in place following this opinion.
